The holy grail of new drug development: India continues to grapple with the challenges of new drug development

The Digital Institutional Repository of IIM Bangalore

Please use this identifier to cite or link to this item: https://repository.iimb.ac.in/handle/2074/13161

DC Field	Value	Language
dc.contributor.author	Krishnan, Rishikesha T
dc.date.accessioned	2020-07-09T15:04:55Z	-
dc.date.available	2020-07-09T15:04:55Z	-
dc.date.issued	2013-07-04
dc.identifier.uri	https://repository.iimb.ac.in/handle/2074/13161	-
dc.description	The Hindu Business Line, 04-07-2013
dc.description.abstract	The announcement by Zydus Cadila in early June that their new drug to treat diabetics who also suffer from high cholesterol has passed all stages of clinical trials is an important landmark for the Indian pharmaceutical industry. This is not the first new chemical entity (NCE) developed by an Indian company. Ranbaxy, DRL, and Biocon are some of the companies that developed NCEs earlier. But none of these NCEs reached the market (so far), mainly due to hiccups faced at one of the later stages of trials. Read more at: https://www.thehindubusinessline.com/news/variety/the-holy-grail-of-new-drug-development/article23031250.ece
dc.language.iso	en_US
dc.publisher	THG Publishing Pvt. Ltd.
dc.subject	Pharmaceutical industry
dc.subject	Drug manufacturing
dc.subject	Drug development
dc.title	The holy grail of new drug development: India continues to grapple with the challenges of new drug development
dc.type	Magazine and Newspaper Article
dc.identifier.url	https://www.thehindubusinessline.com/news/variety/the-holy-grail-of-new-drug-development/article23031250.ece
dc.journal.name	The Hindu Business Line
Appears in Collections:	2010-2019

Check